Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03645824 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)

Study acronym: HOVON134MF
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 22, 2022 (before its estimated July 2023 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Sep 2022 to Jul 2023 Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 70 to confirmed 61 · Completion date: Mar 2023 to Feb 2027 · 1 morev7 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 70 to confirmed 61
    • Completion date: Mar 2023 to Feb 2027
    • Site details revised at 12 of 12 sites
  2. Re-verified, no change to tracked fieldsv6
  3. Study sites: 1 to 12v5
  4. Study sites: 9 to 1v4
  5. Re-verified, no change to tracked fieldsv3
  6. Site details revised at 6 of 9 sitesv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The only curative treatment for patients with myelofibrosis (MF) is allogeneic stem cell transplantation (SCT). Treatment with JAK2 inhibitors like pacritinib improves condition of MF patients, decreases spleen size and might diminish graft-versus-host disease (GvHD), thereby improving the outcome of SCT.
Trial Details
NCT Number NCT03645824
Lead Sponsor Stichting Hemato-Oncologie voor Volwassenen Nederland
Collaborators: Dutch Cancer Society, CTI BioPharma
Conditions Myelofibrosis
Enrollment 61 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov